Biote to Present at 35th Annual Roth Conference

Rhea-AI Summary

Biote Corp. (Nasdaq: BTMD), a leader in personalized hormone therapy, will participate in the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, CA. CEO Terry Weber and CFO Samar Kamdar will present on March 14 at 10:00 a.m. local time, alongside Chairman Marc Beer in investor meetings. Biote focuses on hormone optimization therapies, addressing a $7 billion global market, providing affordable solutions for symptoms related to hormone-related aging. Forward-looking statements in the release highlight potential risks and uncertainties regarding future performance.

IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the 35^th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, CA.

Biote’s Chief Executive Officer, Terry Weber, and Chief Financial Officer, Samar Kamdar, will present at the conference on March 14, 2023, at 10:00 a.m. local time. Ms. Weber, Mr. Kamdar, and Marc Beer, Biote’s Chairman, will also participate in investor meetings throughout the conference.

About Biote

Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Biote’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005291/en/

Investor Relations:

Eric Prouty

AdvisIRy Partners

eric.prouty@advisiry.com



Media:

Press@biote.com

Source: biote Corp.

FAQ

When is Biote participating in the Roth Conference?

Biote is participating in the 35th Annual Roth Conference from March 12-14, 2023.

Who will represent Biote at the Roth Conference?

CEO Terry Weber and CFO Samar Kamdar will represent Biote, along with Chairman Marc Beer.

What will Biote present at the conference?

Biote will present on March 14, 2023, at 10:00 a.m. local time.

What market does Biote target with its hormone therapy?

Biote targets a $7 billion global market for hormone-related aging conditions.

What does Biote specialize in?

Biote specializes in personalized hormone optimization therapies.